As EU criticises healthcare inefficiencies, generics manufacturers poised to swoop

25 May 2018

Several European countries — including Ireland, Italy and Portugal — have been singled out by the European Commission over inefficiencies in their healthcare services as part of the European Union's (EU) annual semester reports.

Portugal, in particular, received strong criticism, with the report strongly urging the country to "strengthen expenditure control, cost-effectiveness and adequate budgeting," in the health sector, which is funded in large part by the taxpayer.

The reports have prompted Medicines for Europe (MFE) — a trade group for European generics and biosimilars manufacturers — to issue a report of its own, promoting the generic and biosimilar alternatives to branded pharma products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK